United States-based Mylan and Netherlands-based Synthon have received a favourable decision in the UK High Court of Justice in their dispute regarding the patent of Israel-based Teva Phamaceutical Industries' multiple sclerosis drug, Copaxone, which was ruled to be invalid because of obviousness, it was reported on Friday.
Synthon is the partner of the United States-based Mylan for the development and supply of its Glatiramer Acetate Injection 40mg/mL product across Europe.
The three-times-a-week injection is the substitutable generic version of Teva's Copaxone 40mg/mL, which had received approval from the US Food and Drug Administration (FDA) earlier this month. The company further stated that the positive judgment gained in the United Kingdom for the Copaxone generic will help further clear the way for its launches of Glatiramer Acetate Injection 40mg/mL in the future in select European markets.
Teva stated that it is disappointed and disagrees with the ruling over its patent, and intends to appeal against it in the UK Court of Appeal, as reported in The Times of Israel.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US